Centessa Pharmaceuticals plc (NASDAQ:CNTA) CTO Tia L. Bush Sells 11,000 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CTO Tia L. Bush sold 11,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $16.86, for a total value of $185,460.00. Following the completion of the transaction, the chief technology officer now directly owns 121,503 shares of the company’s stock, valued at $2,048,540.58. This trade represents a 8.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Centessa Pharmaceuticals Stock Performance

CNTA opened at $16.41 on Wednesday. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of -10.73 and a beta of 1.53. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. Centessa Pharmaceuticals plc has a 1-year low of $7.38 and a 1-year high of $18.97. The business has a 50 day moving average price of $16.75 and a two-hundred day moving average price of $15.27.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. Research analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CNTA has been the subject of a number of recent analyst reports. TD Cowen initiated coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating for the company. Guggenheim upped their target price on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Centessa Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $25.83.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after acquiring an additional 826 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Centessa Pharmaceuticals by 29.1% during the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after acquiring an additional 865 shares during the last quarter. Atria Investments Inc lifted its position in shares of Centessa Pharmaceuticals by 7.0% during the 3rd quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock valued at $274,000 after acquiring an additional 1,116 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Centessa Pharmaceuticals by 39.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company’s stock valued at $317,000 after acquiring an additional 5,316 shares during the last quarter. Finally, Walleye Capital LLC acquired a new stake in shares of Centessa Pharmaceuticals during the 3rd quarter valued at $187,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.